The TAILORx study has demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype DX® test do not need chemotherapy after surgery.
Browsing: breast cancer
In a medical breakthrough, a new approach to immunotherapy has led to complete regression of breast cancer in a patient unresponsive to all other treatments.
Today’s plenary session has revealed some of the biggest stories from ASCO; find out further details of CARMENA, KEYNOTE-042 and TAILORx plus much more by clicking the link below.
The Phase III TAILORx clinical trial results indicate that most women with a specific early-stage breast cancer and midrange score on a gene expression assay do not need chemotherapy after surgery.
Results from a Phase lll clinical trial demonstrate the success of a new targeted medicine, taselisib, in treating advanced breast cancer.
It can be a minefield to know which talks to look out for at ASCO! To help you navigate the largest conference in oncology, we have selected key talks for you to attend at ASCO18.
The primary objective of TAILORx is to more precisely determine the effect of chemotherapy, if any, for women with node-negative, hormone receptor-positive disease and Oncotype DX Breast Recurrence Score® results of 11–25.
Advanced triple-negative breast cancer patients who have inherited a BRCA mutation are twice as likely to benefit from carboplatin as docetaxel, a novel study suggests.
Find out the key features of the breast tumor microenvironment as well as putative predictive biomarkers established in other tumor types. Insights from both fields could guide future studies to enable personalized breast cancer immunotherapy.
Discover the latest news from the 11th European Breast Cancer Conference taking place in Barcelona, Spain (21–23rd March).